APA (7th ed.) Citation

A, K., G, D., A, A., N, T., M, S., E, P., . . . A, B. (2023). Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children. Vaccine, 41(19), 3066. https://doi.org/10.1016/j.vaccine.2023.04.008

Chicago Style (17th ed.) Citation

A, Kawade, et al. "Effect of Reduced Two-dose (1+1) Schedule of 10 and 13-valent Pneumococcal Conjugate Vaccines (SynflorixTM and Prevenar13TM)) on Nasopharyngeal Carriage and Serotype-specific Immune Response in the First Two Years of Life: Results from an Open-labelled Randomized Controlled Trial in Indian Children." Vaccine 41, no. 19 (2023): 3066. https://doi.org/10.1016/j.vaccine.2023.04.008.

MLA (9th ed.) Citation

A, Kawade, et al. "Effect of Reduced Two-dose (1+1) Schedule of 10 and 13-valent Pneumococcal Conjugate Vaccines (SynflorixTM and Prevenar13TM)) on Nasopharyngeal Carriage and Serotype-specific Immune Response in the First Two Years of Life: Results from an Open-labelled Randomized Controlled Trial in Indian Children." Vaccine, vol. 41, no. 19, 2023, p. 3066, https://doi.org/10.1016/j.vaccine.2023.04.008.